Multiple Sclerosis Trial, Recruiting NCT07225868 Sponsor: Universiteit Leiden Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Multiple Sclerosis Trial, Recruiting

NCT07225868
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with relapsing-remitting or secondary progressive multiple sclerosis (MS), confirmed using a specific set of diagnostic standards known as the McDonald 2017 criteria
  • People whose MS-related disability falls below a certain level, as measured by a standard MS disability scale (a score below 7 out of 10)
  • People who have not had a relapse (a flare-up of MS symptoms) for at least 3 months before joining
  • People whose MS medication has remained the same for at least 2 months before joining
  • People aged between 18 and 65 years old
  • People who speak Dutch, English, or German (depending on which study centre they are attending)

Who may not be able to join:

  • People who score very highly on a personality measure of conscientiousness (a score of 65 or above on a specific standardised scale called the BFI-2)
  • People who have a current or past brain injury, or any other neurological condition apart from MS
  • People who have a psychiatric condition that significantly affects their thinking, memory, or ability to carry out everyday tasks
  • People taking medications or using substances that are known to affect thinking or memory
  • People in the Dutch part of the study who are having an MRI scan and have a medical reason why an MRI would not be safe for them (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Hanneke E Hulst, Prof, Leiden University

Phone: 062 831 93 32

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Universiteit Leiden
Registry
ClinicalTrials.gov
Start date
1 November 2025
Est. completion
31 December 2028

Where this trial is recruiting

🇳🇱 Netherlands 🇨🇭 Switzerland 🇺🇸 United States

Primary endpoints

Objective cognitive changes between baseline and post-intervention; Subjective cognitive changes between baseline and post-intervention

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov